309 results on '"Van Der Ende, Marchina"'
Search Results
2. HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
3. The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors
4. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1–Infected Women
5. Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors
6. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
7. Genotypic and Phenotypic Characterization of Replication-Competent HIV-2 Isolated from Controllers and Progressors
8. DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift
9. Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy
10. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients
11. Peginterferon Alfa-2a for AIDS-Associated Kaposi Sarcoma: Experience With 10 Patients
12. Hepatitis B Surface Antigen Decline and Clearance During Long-Term Tenofovir Therapy in Patients Coinfected With HBV and HIV
13. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy
14. Current and future applications of dried blood spots in viral disease management
15. Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience, Compared with Treatment-Naive Patients: The ATHENA Cohort Study
16. A Prospective Open Study of the Efficacy of High-Dose Recombinant Hepatitis B Rechallenge Vaccination in HIV-Infected Patients
17. The pharmacokinetics of abacavir 600 mg once daily in HIV-1-positive pregnant women
18. Long-term Therapy With Tenofovir Is Effective for Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis B Virus
19. Low Risk of Treatment Failure after Substitution of Nevirapine for Protease Inhibitors among Human Immunodeficiency Virus-Infected Patients with Virus Suppression
20. Imiquimod 5% cream for five consecutive days a week in an HIV-infected observational cohort up to 32 weeks in the treatment of high-grade squamous intraepithelial lesions
21. How does weight influence tenofovir disoproxil-fumarate induced renal function decline?
22. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women
23. Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases
24. Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population
25. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals
26. Photodynamic therapy with systemic meta-tetrahydroxyphenylchlorin in the treatment of anal intraepithelial neoplasia, grade 3
27. HIV-associated Idiopathic Noncirrhotic Portal Hypertension: Risk factors And Association With Didanosine: 1179
28. Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
29. Early versus Deferred Antiretroviral Therapy for HIV
30. Long-term survival after kidney transplantation in an HIV-positive patient
31. Complete clinical and virological remission of refractory HIV-related Kaposiʼs sarcoma with pegylated interferon alpha
32. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism
33. Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications
34. Nelfinavir and nevirapine side effects during pregnancy
35. Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy
36. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study
37. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients
38. Post-exposure prophylaxis
39. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women
40. Limited Patient Adherence to Highly Active Antiretroviral Therapy for HIV-1 Infection in an Observational Cohort Study
41. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression
42. Once-daily indinavir plus ritonavir: preliminary results of the PIPO study
43. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine
44. Antiretroviral Therapy in Patients with Dual Infection with Human Immunodeficiency Virus Types 1 and 2
45. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
46. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience
47. Substituting nevirapine for protease inhibitors because of intolerance
48. CD4 T cells remain the major source of HIV-1 during end stage disease
49. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
50. Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.